Comparing to IDH1/IDH2-wt patients, AML with R172 IDH2 mutation revealed higher expression of APP, CXCL12, PAWR, CDC42BPA, and SPARC genes, and decreased expression of KYNU, SUCLG2, CD93, LY86, LIST1 and PTHR2. This evidence concerns the gene IDH1 and acute myeloid leukemia.